Company Media

Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University.

Shares of Immuron Ltd. IMRN, -2.72% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary....

Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.

Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.

Biopharmaceutical company Immuron (IMC) has executed its previously announced research agreement involving the US Naval Medical Research Centre and the CSIRO.

Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND....

The U.S.-listed shares of Immuron Ltd.  skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center (NMRC) has requested.....

Research surveys have shown that around one in four travellers changes their travel itinerary due to diarrhoea and around 5% have to seek medical attention.

The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.

The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.

Australian biopharmaceutical group, Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to its strong share

Travelan featured on The Not Old Better Show with Dr.Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research. Dr Hailey is currently engaged in the investigation of immune responses to Shigella vaccines in pre-clinical/ human clinical

Immuron CEO - Dr Jerry Kanellos interviewed on the Red Chip Money Report, USA. Immuron: Developing Innovative Immunotherapy Therapies for Gut-Mediated Diseases

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut mediated pathogens.

The studies were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.

In January, Immuron (ASX:IMC) released a study of its Travelan tablets by the DOD which showed its was effective in preventing travellers diarrhoea in 180 strains of campylobacter.

There’s no arguing against the ‘breast is best’ mantra at long-standing Melbourne based biotech Immuron, which bases its therapeutics on the goodness of colostrum (the antibody-rich milk produced by mammals after birth).

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.

Shares in pharmaceutical company Immuron Limited surged by 80% when it announced promising results in testing its anti-inflammation drug. The Australian microbiome is developing and commercialising treatments for inflammatory and infectious diseases.